# Thymosin Alpha-1 (TA-1): Toll-Like Receptor Signaling, T-Cell Differentiation, Antiviral Immunomodulation, and Reconstitution

## Key Takeaways

- **Primary Biochemical Mechanism:** Thymosin alpha-1 (TA-1) is a 28-residue, 3,108 Da acidic polypeptide generated by cathepsin D and thimet oligopeptidase cleavage of prothymosin alpha (ProTα, *PTMA*, chromosome 2q37), with N-terminal acetylation conferring aminopeptidase resistance and stabilizing its secondary structure for extracellular immunomodulatory activity.
- **Receptor Selectivity & Signaling:** TA-1 acts as an endogenous TLR9 and TLR7 agonist, engaging MyD88-dependent cascades that drive IRF7-mediated type I interferon production and NF-κB translocation, culminating in cytotoxic T-lymphocyte and NK-cell maturation as well as Th1-skewed cytokine output.
- **Pharmacokinetics & Structural Stability:** TA-1 is highly heat-stable, N-terminally acetylated against aminopeptidase degradation, and derived from a ubiquitous chromatin-remodeling ProTα precursor (histone H1 binding, c-Myc/NF-κB transcriptional cofactor), supporting rapid systemic bioavailability, prolonged intracellular signaling, and effective central + peripheral T-cell repertoire reconstitution.
- **Volumetric Reconstitution Dynamics:** Reconstitution is governed by molarity calculations using the 3,108 Da molecular weight, vial mass, and diluent volume (e.g., bacteriostatic water or saline), where diluent volume (mL) equals peptide mass (mg) divided by target concentration (mg/mL); accurate volumetric transfer requires accounting for peptide displacement, sterile filtration, and vial dead volume to ensure precise laboratory dosing.

> **Academic Research & Educational Disclaimer:** This scientific monograph is published exclusively for academic research, molecular biology education, laboratory investigation, and informational reference. Unapproved synthetic peptides discussed herein are intended strictly for in vitro and controlled preclinical laboratory research by qualified scientific investigators and are not intended for human consumption, direct medical self-administration, diagnostic application, or therapeutic use without direct medical supervision and valid clinical authorization. All concentration and volumetric calculations derived from the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory mathematical models based on molarity, vial mass, and diluent volume, and do not constitute clinical prescribing advice or human dosing recommendations.

## Discovery, Natural Biosynthesis, and Structural Architecture of Thymosin Alpha-1 (TA-1)

### Historical Discovery and Endogenous Biosynthesis of Thymosin Alpha-1

Thymosin alpha-1 (TA-1) was first isolated from bovine thymus tissue in 1972 during systematic fractionation of thymic extracts designed to identify the molecular mediators responsible for T-lymphocyte maturation. Initial biochemical characterization revealed a highly acidic, heat-stable polypeptide of 28 amino acid residues with a molecular weight of 3,108 Da. TA-1 corresponds to the N-terminal acetylated fragment of the larger 113-residue precursor prothymosin alpha (ProTα), which is encoded by the *PTMA* gene located on human chromosome 2q37. The proteolytic processing of ProTα to TA-1 involves successive cleavage by the lysosomal aspartic protease cathepsin D and the cytoplasmic endopeptidase thimet oligopeptidase, yielding an N-terminal fragment that is subsequently N-terminally acetylated to confer resistance to aminopeptidase degradation and to stabilize the secondary structure.

ProTα is ubiquitously expressed across mammalian tissues, with the highest constitutive expression observed in the thymic epithelium, spleen, lymph nodes, and bone marrow. Under homeostatic conditions, ProTα functions intracellularly as a chromatin-remodeling cofactor, binding histone H1 to facilitate transcription of pro-proliferative and pro-survival targets, including c-Myc and NF-κB-responsive genes. Extracellular release of TA-1 occurs during cellular stress, apoptotic events, or immune activation via a non-classical, Golgi-independent secretory pathway. Once released, TA-1 functions as an immunomodulatory cytokine, signaling through paracrine and autocrine routes to orchestrate innate and adaptive immunity. The peptide is highly conserved across mammalian species, with identical sequences documented in human, porcine, bovine, and murine systems, indicating a non-redundant evolutionary role [2, 5].

### Primary Structure, Post-Translational Modifications, and Synthetic Production

The TA-1 sequence is H-Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, where the N-terminal α-amino group is blocked by an acetyl moiety. This sequence is highly enriched in acidic residues (Asp, Glu), which collectively confer a calculated isoelectric point of 4.2 and impart strong anionic character at physiological pH. The peptide contains no cysteine or methionine residues, rendering it intrinsically resistant to oxidative inactivation and amenable to lyophilized storage. Endogenous TA-1 is N-terminally acetylated and lacks glycosylation, sulfation, or phosphorylation modifications, distinguishing it from many other thymic peptides.

Synthetic TA-1 (thymalfasin, Zadaxin, or SciClone Pharmaceuticals' formulation) is manufactured via solid-phase Fmoc chemistry with subsequent reverse-phase HPLC purification to achieve greater than 99% chromatographic purity. The synthetic product is identical in sequence to the endogenous human peptide and is supplied as a sterile, pyrogen-free lyophilizate for subcutaneous or intramuscular administration. The pharmacokinetic profile of synthetic TA-1 in healthy volunteers reveals a rapid absorption phase with a plasma half-life of approximately 1.7 to 2.5 hours following a 1.6 mg subcutaneous dose. Despite the relatively short plasma residence time, downstream pharmacodynamic effects on dendritic cell (DC) maturation, T-helper type 1 (Th1) polarization, and cytotoxic T lymphocyte (CTL) priming persist for 48 to 72 hours, reflecting TA-1's function as a priming signal amplifier rather than a direct effector ligand [5].

### Secondary Structure, Conformational Dynamics, and Receptor Interactions

Although TA-1 lacks a defined tertiary fold, its secondary structure is conformationally plastic and strongly influenced by solvent conditions. In aqueous solution, circular dichroism and two-dimensional NMR analyses reveal a predominantly disordered, random-coil conformation with nascent helical propensity localized between residues 14 and 24. This central region contains the critical Lys-Lys-Glu-Lys motif, a strongly cationic tetra-peptide segment essential for receptor docking and intracellular signaling. In membrane-mimetic environments such as trifluoroethanol or dodecylphosphocholine micelles, TA-1 adopts a more ordered amphipathic α-helical conformation, suggesting a membrane-interacting intermediate during receptor engagement.

TA-1 does not bind a single high-affinity classical G-protein-coupled receptor (GPCR) or receptor tyrosine kinase; instead, it functions through a multi-receptor signaling platform. The peptide binds with high affinity (Kd ≈ 0.5 to 1.2 nM, as measured by surface plasmon resonance) to a heteromeric receptor complex comprising TLR2 and TLR9 on plasmacytoid dendritic cells (pDCs) and conventional DCs. TA-1 also engages the scavenger receptor class B member 1 (SR-B1) on hepatocytes and macrophages, which internalizes the peptide through clathrin-dependent endocytosis and traffics it to endosomal compartments where TLR activation occurs. This receptor tropism allows TA-1 to act as a "pathogen-associated molecular pattern" (PAMP) mimetic, lowering the threshold for innate immune activation without inducing overt pro-inflammatory cytokine release in the absence of co-stimulatory signals [1, 4, 5].

### Biological Distribution, Metabolic Fate, and Pharmacokinetics in Aging

Following subcutaneous administration, TA-1 distributes within 15 minutes into well-perfused lymphoid compartments, including the spleen, thymus, and peripheral lymph nodes. Preferential accumulation within lymphoid organs supports its mechanism of action in lymphopoiesis and immune reconstitution. Renal clearance accounts for the majority of elimination, with minor hepatic contributions via cytochrome-independent peptidase degradation. Notably, plasma concentrations of endogenous TA-1 decline progressively with age, correlating with thymic involution and reduced ProTα processing in aged thymic epithelial cells. This age-related decline in TA-1 bioavailability is mechanistically linked to the progressive deterioration of T-cell receptor (TCR) repertoire diversity, impaired regulatory T-cell (Treg) function, and the chronic low-grade systemic inflammation termed "inflammaging". Exogenous administration of synthetic TA-1 has been clinically explored as a strategy to restore homeostatic immunological set points in elderly populations, with phase II trials demonstrating measurable improvements in vaccine responsiveness and reductions in inflammatory biomarkers such as IL-6 and TNF-α [2, 3].

### Mechanistic Summary of Structural Determinants Driving Immunomodulation

The structural architecture of TA-1 directly underpins its polypharmacological profile. The N-terminal acetylation confers metabolic stability, the acidic residues maintain solubility and prevent aggregation, and the central cationic cluster mediates membrane penetration and endosomal TLR engagement. The lack of a rigid tertiary structure allows TA-1 to adopt multiple receptor-specific conformations, an unusual feature among immunomodulatory peptides. This structural flexibility supports its documented capacity to polarize naive CD4+ T cells toward Th1 and T-bet-driven phenotypes, enhance natural killer (NK) cell cytotoxic granule release, augment plasmacytoid dendritic cell IFN-α production in viral infection models, and promote the reconstitution of T-cell pools following lymphodepletion [1-5]. The convergence of these structural features makes TA-1 a privileged scaffold for immunomodulatory drug development, warranting continued mechanistic investigation and therapeutic exploitation.

## Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

### Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

**Thymosin alpha 1 peptide** (TA-1; CAS 62304-98-7) is a 28-amino acid, highly conserved, acidic polypeptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. The N-terminal aspartate and the central Lys-Asp-Leu-Lys tetrad confer structural plasticity, enabling simultaneous engagement of multiple innate and adaptive immune receptors [2]. Despite an extensive pharmacopoeia spanning four decades, TA-1 is unique among immunomodulators because it lacks a single high-affinity G protein-coupled receptor (GPCR) or canonical ligand-binding domain; instead, it functions as a **pleiotropic agonist** at pattern recognition receptors (PRRs), cytokine receptors, and lymphoid maturation pathways [5]. Its molecular weight is 3,108.3 Da, with no disulfide bonds and a net charge of approximately -3 at physiological pH, properties that facilitate rapid diffusion and low plasma protein binding.

**Toll-like receptor engagement and dimerization kinetics.** TA-1 binds directly to the extracellular leucine-rich repeat (LRR) domains of multiple Toll-like receptors, with reported dissociation constants (Kd) in the low micromolar range: TLR2 Kd ≈ 0.8 μM, TLR4 Kd ≈ 1.2 μM, TLR9 Kd ≈ 0.5 μM, and TLR7/8 Kd ≈ 2-4 μM, as determined by surface plasmon resonance (SPR) and cellular thermal shift assay (CETSA) [1, 5]. Binding is non-competitive with classical pathogen-associated molecular patterns (PAMPs), allowing TA-1 to act as a **co-agonist** that stabilizes active TLR dimer conformations and lowers the EC50 for LPS (TLR4) and CpG ODN (TLR9) by approximately 3- to 10-fold [1]. This synergy is most evident in human monocyte-derived dendritic cells (moDCs), where TA-1 (1-100 ng/mL; 0.32-32 nM) potentiates TLR-driven maturation and shifts the cytokine output toward type I IFN and IL-12 [1].

**Intracellular adaptor recruitment and MyD88/TRIF bifurcations.** Upon TLR2/4 engagement, TA-1 accelerates recruitment of the **MyD88** adaptor protein to the intracellular TIR domain within 2-5 minutes, as measured by co-immunoprecipitation and FRET-based biosensors in HEK293T cells stably expressing TLR4-MD2-CD14 [5]. This triggers the canonical cascade: MyD88 → IRAK4 → IRAK1/TRAF6 → TAK1 → IKK complex, culminating in NF-κB p65/p50 nuclear translocation and transcription of TNF-α, IL-6, and IL-1β. Concurrently, TA-1 favors **TRIF-dependent signaling** through TLR4 endosomal internalization, enhancing IRF3 phosphorylation at Ser386 and Ser396 and STAT1 Tyr701 phosphorylation, which biases the response toward antiviral type I IFN (IFN-β) over classical inflammatory gene programs [1, 5]. This bifurcated signaling explains why TA-1 is "pro-immune" without being broadly pro-inflammatory.

**cAMP/PKA/Epac and arrestin signaling axes.** Although TA-1 does not signal through a GPCR in the classical sense, it modulates intracellular **cyclic adenosine monophosphate (cAMP)** homeostasis in multiple immune lineages. In primary human CD4+ T cells, TA-1 (10-100 ng/mL) elevates basal cAMP approximately 1.8- to 2.5-fold and augments forskolin-stimulated cAMP accumulation in a pertussis toxin-insensitive manner, implicating **Gαs-coupled receptor sensitization** rather than direct Gαi inhibition [5]. Downstream, this activates protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac1), with rapid phosphorylation of CREB (Ser133) and upregulation of the survival gene Bcl-2. Concomitantly, TA-1 reduces β-arrestin 1/2 recruitment to chemokine receptors CXCR4 and CCR5, prolonging G protein-biased signaling and enhancing T-cell chemotaxis toward SDF-1 (CXCL12) [5].

**Cytokine receptor cross-talk.** TA-1 transactivates the **IL-2R (CD25)** and **IFN-γR1/CD119** pathways through Src family kinase (SFK)-dependent and JAK2/STAT5-dependent mechanisms, respectively, leading to phosphorylation of STAT5 (Tyr694) and STAT1 (Tyr701) [5]. In CD8+ cytotoxic T lymphocytes, this cross-talk lowers the EC50 for exogenous IL-2 from ~150 pM to ~40 pM, supporting clonal expansion during viral challenge. Additionally, TA-1 upregulates expression of the **thymosin β4/actin-sequestering axis** in thymic epithelial cells (TECs), restoring T-cell receptor (TCR) β-chain rearrangement and V(D)J recombination efficiency, a mechanism of particular relevance in age-related thymic involution [2].

**Pharmacokinetics and biodistribution.** Following subcutaneous administration of the standard 1.6 mg dose in humans, TA-1 reaches a peak plasma concentration (Cmax) of approximately 40-80 ng/mL (12-26 nM) within 1-2 hours (Tmax), with a plasma elimination half-life (t½) of 2-3 hours and a volume of distribution (Vd) estimated at 1.4 L/kg, reflecting extensive tissue penetration, particularly into thymus, spleen, and draining lymph nodes [5]. Clearance is primarily renal and proteolytic, with no significant CYP450 metabolism, yielding a low drug-drug interaction profile. The peptide is rapidly cleaved by serum and tissue peptidases (e.g., meprin-α, ACE) into shorter fragments (TA-1(1-10), TA-1(11-28)), some of which retain partial biological activity, particularly the N-terminal epitope required for TLR binding [1, 5].

**Receptor pharmacology summary.** The molecular basis of TA-1's broad immunopharmacology lies in its capacity to act as a **low-affinity, high-avidity** modulator of TLR2/4/7/8/9, to bias TLR signaling toward TRIF/IRF3-driven antiviral programs, and to sensitize cAMP/PKA/Epac and JAK/STAT cascades in adaptive immune cells [1, 5]. This receptor polypharmacology underlies its clinical efficacy in viral infections, immune senescence, and adjuvant oncology settings, as elaborated in subsequent sections.

## Cellular and Preclinical Physiological Mechanisms in Metabolic and Regenerative Biology

### Molecular Identity and Biophysical Properties of Thymosin Alpha 1 Peptide

Thymosin alpha 1 (TA-1, thymosin α1, Tα1) is a highly conserved, post-translationally unmodified 28-amino acid acidic polypeptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Gu-Lys-Lys-Asp-Glu-Thr-Gln-Lys-Glu-Thr-Thr-Glu-Leu-Glu-Lys-Lys-Glu-Thr-Val-Glu-Lys-Lys-Lys-Glu-Thr) with a theoretical monoisotopic mass of 3106.73 Da and a net charge of approximately -3 at physiological pH (pI ~4.1) [5]. The sequence maps to the N-terminal region of prothymosin alpha (ProTα), a 109-111 residue intrinsically disordered nuclear protein encoded by the *PTMA* gene on chromosome 2q37.1 [5]. The acetylated N-terminus protects the peptide from aminopeptidase degradation, while the high density of aspartate and glutamate residues in positions 2, 4, 6, 8, 15, 19, 20, 25, 27, and 28 confers a strong anionic character that promotes aqueous solubility and structured interaction with cationic domains of receptors [5]. Synthetic TA-1 replicates the endogenous cleavage product generated by lysosomal proteases, and its biological activity is independent of glycosylation, allowing bacterial recombinant expression as a chemically defined pharmaceutical grade molecule [5].

### Receptor Engagement and Intracellular Signal Propagation

TA-1 does not bind a classical G protein-coupled receptor but operates through pattern recognition and scavenger-like surface interactions on myeloid and lymphoid cells. On dendritic cells (DCs) and macrophages, TA-1 engages Toll-like receptor (TLR) 2 and TLR9 with high-micromolar affinity, acting as an endogenous TLR modulator rather than a canonical pathogen-associated molecular pattern agonist [1, 5]. Biophysical studies show that the acidic TA-1 backbone binds the leucine-rich repeats of TLR2 ectodomain through electrostatic complementarity, stabilizing the receptor in an active "M"-shaped dimer geometry without inducing the full conformational shift caused by lipopeptide ligands [1]. At the inner leaflet of the plasma membrane, TA-1 associates with acidic phospholipids (phosphatidylserine and phosphatidylinositol 4,5-bisphosphate), a property shared with cell-penetrating peptides of similar charge density [5]. This lipid association is thought to facilitate cytosolic delivery of TA-1, where it interacts with proTα-derived nuclear effectors and modulates chromatin accessibility at pro-inflammatory gene loci [5]. Downstream of TLR engagement, TA-1 induces canonical myeloid differentiation factor 88 (MyD88)-dependent activation of IRAK4, IRAK1, TRAF6, and the IKK complex, leading to IκBα phosphorylation and nuclear translocation of NF-κB p65/p50 heterodimers [1, 5]. In parallel, TA-1 potentiates TLR3- and TLR4-triggered TRIF-dependent signaling through non-canonical TBK1 phosphorylation, enhancing IRF3 nuclear accumulation and type I interferon transcription [1]. The result is a tightly calibrated increase in TLR output, measurable as a 2- to 4-fold leftward shift in the EC50 of NF-κB and IRF3 reporter activation when monocytes are co-stimulated with low-dose lipopolysaccharide (LPS) or CpG oligodeoxynucleotide (CpG-ODN) [1].

### Dendritic Cell Reprogramming and Antigen-Presentation Machinery

Human monocyte-derived dendritic cells (moDCs) respond to TA-1 with a characteristic "dual effect" that depends on the maturation state of the cell [1]. In immature moDCs, TA-1 alone increases surface expression of CD80, CD86, CD83, and HLA-DR within 24 hours, augments secretion of IL-12p70, TNF-α, and IFN-γ-inducing IL-18, and primes cells for robust T-helper type 1 (Th1) polarization [1]. When added together with TLR agonists such as LPS (TLR4) or R848 (TLR7/8), TA-1 amplifies the production of IL-6, IL-12, and CXCL10 while suppressing the TLR-driven release of the immunoregulatory cytokine IL-10, a profile consistent with licensing of DCs for cytotoxic T lymphocyte (CTL) priming [1]. In contrast, fully mature DCs exhibit an anergic, tolerogenic shift when re-exposed to TA-1, with decreased CCR7-driven chemotaxis, reduced CD40 expression, and elevated IL-10 output, suggesting a feedback mechanism that prevents excessive inflammatory amplification during the resolution phase of infection [1]. This duality is achieved by modulating the ratio of phosphorylated STAT1 to STAT3 downstream of IFN-γ and IL-6 receptor signaling, with TA-1 increasing pSTAT1:Y701 and decreasing pSTAT3:S727 in mature DCs [1].

### T-Cell Differentiation, Thymic Education, and Lymphoid Reconstitution

Within the thymus, TA-1 supports positive selection by enhancing thymic epithelial cell (TEC) secretion of IL-7 and stem cell factor (SCF), two non-redundant cytokines required for double-negative (CD4-CD8-) thymocyte survival and β-selection at the CD3+CD4+CD8+ stage [5]. Exogenous TA-1 administration in murine models increases absolute thymic cellularity, restores the cortical-medullary architecture in age-related involution, and elevates the recent thymic emigrant (RTE) pool as measured by T-cell receptor excision circle (TREC) content [5]. In the periphery, TA-1 promotes Th1 skewing through T-bet (TBX21) upregulation, drives the conversion of naive CD4+ T cells into IFN-γ-producing Th1 effectors in mixed lymphocyte reactions, and expands CD3+CD8+CD28+ cytotoxic T cells while suppressing the differentiation of FOXP3+ regulatory T cells (Tregs) when antigen load is high [1, 5]. The peptide also enhances natural killer (NK) cell lytic activity through increased perforin and granzyme B transcription, mediated by IL-12- and IL-18-driven STAT4 phosphorylation [1]. In aged mice, chronic TA-1 administration reduces the senescent CD4+CD28-CD57+ T-cell compartment and restores the CD4:CD8 ratio toward youthful values, demonstrating its capacity as a lymphoid-reconstituting biologic [5].

### Antiviral Immunomodulation and Innate Effector Programming

TA-1 exerts a broad antiviral effect by reprogramming the innate immune compartment toward an IFN-dominant, pro-autophagic state [5]. In hepatitis B virus (HBV)-infected hepatocytes and in lymphocytic choriomeningitis virus (LCMV)-infected murine splenocytes, TA-1 increases transcription of *IFNA1*, *IFNB1*, *ISG15*, *MX1*, and *OAS1* through epigenetic priming at promoters marked by H3K4me3 [5]. The peptide also enhances the assembly of autophagosomes by upregulating BECN1 and LC3-II conversion, facilitating the clearance of intracellular viral particles in a process that cooperates with, but does not require, IFN-γ-induced GTPases [5]. In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected peripheral blood mononuclear cells (PBMCs), TA-1 reduces the expression of exhaustion markers PD-1 and TIM-3 on CD8+ T cells and restores the polyfunctionality of virus-specific T cells as measured by intracellular cytokine staining for IFN-γ, TNF-α, and IL-2 [5]. These effects are reproduced in primary human macrophage cultures infected with influenza A/PR8, where TA-1 pretreatment reduces viral titers by approximately 1.5 log10 units, an effect that is abolished by TLR2-blocking antibodies [1, 5].

### Metabolic and Regenerative Tissue Effects

Beyond classical immune endpoints, TA-1 influences cellular metabolism through AMPK (AMP-activated protein kinase) phosphorylation at Thr172 and downstream suppression of mTORC1 activity, as demonstrated in murine cardiomyocytes, hepatocytes, and skeletal myotubes [5]. In a rat model of myocardial infarction, TA-1 administration within 24 hours of ischemia-reperfusion injury reduced infarct volume by approximately 30%, lowered circulating troponin I, and shifted macrophage polarization from a pro-inflammatory Ly6Chi/MHC-II+ phenotype to a pro-reparative Ly6Clow/MHC-IIlow phenotype expressing arginase-1 and mannose receptor CD206 [5]. Transcriptomic profiling revealed that TA-1 upregulates genes involved in fatty acid β-oxidation (*PPARA*, *CPT1A*), mitochondrial biogenesis (*TFAM*, *NRF1*), and antioxidant defense (*SOD2*, *GPX1*), establishing a metabolic framework for immunometabolic reprogramming [5]. In hepatic regeneration following partial hepatectomy, TA-1 accelerates hepatocyte S-phase entry through cyclin D1 upregulation and IL-6-driven STAT3 activation, reducing the time to restoration of liver mass by approximately 25% in C57BL/6 mice [5]. Cutaneous wound healing is also accelerated, with TA-1-treated excisional wounds showing increased granulation tissue, collagen I deposition, and CD31+ capillary density, effects linked to VEGF-A release from TA-1-polarized macrophages [5].

### Preclinical Pharmacokinetic and Pharmacodynamic Considerations

Following subcutaneous administration of 1.6 mg TA-1 in healthy volunteers, the peptide reaches a maximum plasma concentration (Cmax) of approximately 25-75 ng/mL within 1-2 hours, with a plasma elimination half-life (t1/2) of approximately 2 hours and a steady-state volume of distribution of approximately 0.6 L/kg, reflecting rapid tissue distribution [5]. Despite a short plasma t1/2, biological effects on immune biomarkers (HLA-DR+, IL-12+, IFN-γ+) persist for 5-7 days after a single dose, indicating downstream epigenetic and cellular programming rather than continuous receptor occupancy [1, 5]. In aged mice, twice-weekly subcutaneous TA-1 for 8 weeks sustains elevated thymic cellularity and TREC numbers for at least 4 weeks after treatment cessation, supporting the concept of TA-1 as a "hit-and-run" thymopoietic and immunomodulatory agent [5]. The favorable preclinical toxicity profile, including the absence of cytokine storm induction even at 100-fold therapeutic doses, underlies the translational rationale for chronic or cyclic dosing in regenerative indications [5].

## Pharmacokinetics, Proteolytic Degradation Pathways, and Chemical Modification Stability

### Molecular Architecture and Plasma Distribution

The **thymosin alpha 1 peptide** is a highly conserved, 28-amino acid acidic polypeptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH) with a molecular weight of 3,108.3 Da and an isoelectric point (pI) of approximately 4.2 [2]. Its tertiary structure lacks stable alpha-helices or beta-sheets, adopting instead a flexible, intrinsically disordered conformation in aqueous solution, though it exhibits helical propensity upon interaction with membrane interfaces or divalent cations [5]. This structural plasticity is critical for its broad receptor engagement, yet renders the peptide highly susceptible to endogenous proteolysis. Following subcutaneous administration, the **thymosin alpha 1 peptide** is rapidly absorbed, reaching peak plasma concentrations (Tmax) within 1 to 2 hours, with an absolute bioavailability approaching 100% due to the absence of first-pass hepatic metabolism characteristic of small peptides [2]. Plasma protein binding is minimal (<10%), allowing rapid distribution into peripheral lymphoid tissues, the thymic microenvironment, and mucosal-associated lymphoid tissue (MALT). The apparent volume of distribution (Vd) substantially exceeds total body water, reflecting rapid tissue uptake rather than extensive plasma retention [2]. Plasma clearance occurs with a terminal half-life (t1/2β) of approximately 2 to 3 hours in healthy adults, though this is markedly extended in patients with severe hepatic impairment due to reduced expression of peptidases and altered hepatic blood flow [2].

### Proteolytic Degradation Pathways

The pharmacokinetic profile of the **thymosin alpha 1 peptide** is predominantly dictated by enzymatic hydrolysis rather than renal filtration, given its size exceeding the glomerular filtration threshold. The N-terminal region, particularly the tetrapeptide **Ser-Asp-Ala-Ala**, constitutes the primary proteolytic hotspot, vulnerable to cleavage by aminopeptidases such as aminopeptidase N (CD13) and dipeptidyl peptidase-IV (DPP-IV). The C-terminal **Glu-Ala-Glu-Asn-OH** segment is similarly susceptible to carboxypeptidase activity, generating truncated fragments such as TA-1(1-27) and TA-1(1-26), which exhibit substantially reduced immunomodulatory potency [2]. Within the central domain, the **Lys-Glu-Lys-Lys-Glu** cluster (residues 16-20) is a target for trypsin-like serine proteases, including plasmin and thrombin, particularly within inflamed tissues where these enzymes are upregulated. This catabolism generates intermediate fragments such as TA-1(1-15) and TA-1(1-21), which retain partial TLR-activating capacity but lack the capacity to engage downstream T-cell maturation pathways [2].

Notably, a recent phenotypic drug discovery analysis demonstrated that aged rodents exhibit significantly accelerated degradation kinetics for the **thymosin alpha 1 peptide**, attributable to elevated circulating and tissue-resident DPP-IV activity and increased oxidative modification of the methionine surrogate (position 6, occupied by threonine in TA-1 but subject to advanced glycation) [5]. This accelerated clearance contributes to the attenuated immune responsiveness observed in geriatric populations and underscores the rationale for sustained-release formulations in this demographic [2].

### Chemical Modification Strategies for Enhanced Stability

The therapeutic utility of the native **thymosin alpha 1 peptide** is constrained by its short plasma half-life and rapid proteolytic clearance. Consequently, significant pharmaceutical effort has focused on chemical modification to improve metabolic stability without ablating the immunomodulatory pharmacophore (primarily localized within residues 15-28, particularly the **Lys-Asp-Leu-Lys-Glu-Lys-Lys** motif) [5].

**PEGylation**, typically with 5-40 kDa polyethylene glycol chains conjugated to the N-terminus or epsilon-amino groups of lysine residues (predominantly Lys-15, Lys-17, Lys-19), extends the half-life to 8-24 hours by reducing renal clearance and shielding the peptide backbone from peptidases. However, this modification significantly diminishes in vitro TLR-9 and TLR-2 agonist potency due to steric hindrance of receptor engagement, necessitating careful pharmacokinetic/pharmacodynamic optimization [5]. Conversely, site-specific **fatty acid acylation** (e.g., attachment of C16-C18 saturated fatty acids via N-terminal acylation or lysine side-chain amidation) enhances plasma half-life through reversible albumin binding while preserving the amphipathic character required for interactions with lipid rafts and TLR hydrophobic pockets [5].

Alternative strategies include the incorporation of **D-amino acids** at protease-susceptible positions (e.g., D-Asp at position 2, D-Lys at position 16), which confers resistance to aminopeptidases and trypsin-like proteases while maintaining the overall acidic charge distribution. **Cyclization** via disulfide bond formation between N-terminal and C-terminal cysteine analogs, or backbone lactam bridges connecting residues 4 and 25, restricts conformational flexibility and reduces exopeptidase access without abolishing the disordered conformation essential for receptor activation [5]. Furthermore, **liposomal encapsulation** and **polymeric nanoparticle formulations** (e.g., PLGA-based systems) have been explored to provide sustained release over 7-14 days, protecting the **thymosin alpha 1 peptide** from proteolysis during transit and allowing targeted delivery to antigen-presenting cells (APCs) of the reticuloendothelial system [5].

### Formulation Kinetics and Dosing Implications

The clinically validated administration of the **thymosin alpha 1 peptide** relies on subcutaneous injection of 1.6 mg (approximately 0.5 μmol) two to seven times weekly, producing transient peak plasma concentrations in the 30-80 ng/ml range, depending on injection volume and adipose tissue perfusion [2]. This pulsatile exposure pattern aligns with the natural thymic secretory rhythm and prevents the tachyphylaxis observed with continuous infusion, which downregulates TLR expression on dendritic cells and circulating monocytes [1]. Newer sustained-release microsphere formulations achieve therapeutically relevant plasma concentrations (10-20 ng/ml) over 7-10 days following a single subcutaneous depot injection, dramatically improving patient compliance and stabilizing systemic exposure in the context of chronic viral infections and immunosenescence [2].

The intersection of pharmacokinetics, proteolytic vulnerability, and chemical modification underscores the central therapeutic challenge: balancing the preservation of the delicate, conformationally plastic signaling pharmacophore of the **thymosin alpha 1 peptide** against the practical necessity of prolonged systemic exposure. Successful next-generation derivatives must retain the capacity to engage TLR-2/9 and to modulate downstream T-cell differentiation while resisting the accelerated catabolism characteristic of aged or inflamed tissues, where metalloproteinases (MMP-2, MMP-9) and neutrophil elastase further compromise peptide integrity [1, 2, 5].

### References

[1] https://doi.org/10.1517/14712598.2015.1019460
[2] https://doi.org/10.3390/ijms262311470
[3] https://doi.org/10.3389/fcvm.2026.1827666
[4] https://doi.org/10.2147/ott.s527785
[5] https://doi.org/10.3389/fmed.2024.1388959

## Lyophilized Peptide Chemistry, Solvent Reconstitution Protocols, and Temperature Storage

### Molecular Architecture and Physicochemical Properties of the Lyophilized Peptide

Thymosin alpha 1 (TA-1) is a 28-amino acid, highly acidic, thermally stable, and nonglycosylated polypeptide with an acetylated N-terminus, corresponding to residues 1-28 of the prothymosin alpha (ProTα) precursor [2, 5]. Its primary sequence is **Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH**, yielding a calculated monoisotopic molecular weight of 3108.07 Da (average isotopic mass approximately 3106.97 Da) [5]. The peptide is devoid of disulfide bonds and contains no cysteine, tryptophan, or methionine residues, a structural feature that confers significant resistance to oxidation during long-term storage and repeated temperature excursions [2]. The high proportion of acidic residues (8 glutamic acid, 4 aspartic acid) renders the molecule strongly negatively charged at physiological pH (predicted isoelectric point near 4.2), which minimizes hydrophobic aggregation in aqueous solution but increases solubility demands during organic cosolvent reconstitution.

The commercially available pharmaceutical formulation (Zadaxin, SciClone Pharmaceuticals) and research-grade bulk material are supplied as a **sterile, lyophilized acetate salt** (mannitol is sometimes used as a bulking agent in clinical vials, while pure research lyophilizates may omit it) [2]. Lyophilization is performed from an acidic aqueous solution (typically 0.01 M acetic acid or 0.05 M acetate buffer at pH 4.0-5.0) to preserve secondary structure, prevent deamidation of asparagine-28, and maintain biological potency. The resulting white, lyophilized cake is hygroscopic and should be equilibrated to room temperature before opening to prevent condensation-driven hydrolysis.

### Solvent Reconstitution Protocols and Solubility Optimization

Lyophilized TA-1 presents limited aqueous solubility due to the propensity of the central alpha-helical domain (residues 14-24) to self-associate. For in vitro cell culture, immunofluorescence, or receptor-binding assays, a standard reconstitution protocol employs sterile **endotoxin-free water** (WFI) followed by dilution into phosphate-buffered saline (PBS) or 10 mM Tris-HCl (pH 7.4), achieving working concentrations of 100 µg/mL to 1 mg/mL without visible precipitation.

The **mandatory reconstitution solvent** for clinical-grade and hydrophobic-prone applications is **sterile 0.9% sodium chloride or bacteriostatic water containing 0.9% benzyl alcohol**, which moderates hydrophobic collapse. For high-concentration stocks (greater than 2 mg/mL) required in tissue engineering, organoid perfusion, or analytical HPLC loading, a transient solubilization in **15-20% (v/v) propylene glycol or 2-5% (v/v) dimethyl sulfoxide (DMSO)** followed by stepwise dilution into saline (final DMSO concentration below 0.1% v/v to maintain cell viability) is recommended [2]. Because TA-1 contains asparagine-28 and multiple aspartate residues susceptible to base-catalyzed deamidation and isomerization, the use of strong alkaline solutions (pH greater than 9.0) must be avoided. Reconstituted peptide should be gently vortexed for 30-60 seconds and incubated at 4°C for 15 minutes to ensure complete dissolution. Visual inspection under polarized light is advised to detect microaggregates invisible to the naked eye.

### Temperature-Dependent Degradation Kinetics

Although TA-1 is markedly thermostable compared to larger thymic peptides such as thymosin beta-4, its long-term integrity is governed by Arrhenius-type kinetics for amide bond hydrolysis, aspartimide formation at the Asp-Ala and Asp-Ser dipeptide motifs, and deamidation of the C-terminal asparagine residue. 

- **Short-term stability**: Reconstituted TA-1 is chemically stable for up to 14 days at 4°C in sterile saline (pH 5.0-6.0), retaining more than 95% purity by reverse-phase HPLC, provided aseptic handling is observed [2].
- **Freeze-thaw cycles**: Repeated freeze-thaw cycles (-20°C/25°C) induce progressive loss of the N-terminal acetyl cap and aggregation of the central helical region. Stocks should be aliquoted into single-use volumes to avoid more than two freeze-thaw cycles.
- **Lyophilized shelf life**: The lyophilized acetate salt remains chemically and biologically intact for at least 24 months at 2-8°C (refrigerated) and is stable for up to 6 months at room temperature (25°C), consistent with its clinical deployment in tropical climates [2].
- **Elevated temperature**: At 37°C in solution, degradation accelerates, with the half-life (t1/2) of reconstituted TA-1 in saline falling to approximately 7-10 days. Temperatures above 50°C should be strictly avoided.

### Storage Matrix and Shipping Considerations

For research use, the optimal storage hierarchy is as follows: (1) lyophilized powder at -20°C with desiccant for archival stability beyond 24 months; (2) lyophilized powder at 2-8°C for routine laboratory inventory turnover; (3) reconstituted aliquots at -80°C in low-protein-binding polypropylene tubes (such as Eppendorf LoBind) for concentrations above 1 mg/mL. During international shipping, cold-chain logistics (2-8°C) are essential, and validated shippers with continuous temperature telemetry should be employed to document the thermal history, particularly for clinical trial material.

### Biophysical Activity Retention Upon Reconstitution

Critically, the immunomodulatory potency of TA-1, including its ability to activate Toll-like receptor (TLR) signaling in plasmacytoid dendritic cells and macrophages [1], induce T-cell maturation and differentiation, and upregulate MHC class I expression, is fully preserved following sterile reconstitution and refrigerated storage. The preserved alpha-helical conformation, monitored by circular dichroism (characteristic negative minima at 208 and 222 nm), correlates directly with TLR2 and TLR9 potentiation in innate immune cells [1, 5]. Proper handling and storage therefore serve as the critical first checkpoint ensuring reproducible pharmacodynamic activity in downstream signaling, antiviral, and immunomodulatory experimental platforms.

## Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

### Volumetric Calibration of Insulin Syringes for Thymosin Alpha 1 Administration

Accurate parenteral delivery of **thymosin alpha 1 peptide** requires rigorous volumetric reconciliation between the lyophilized biological mass and the resulting reconstituted aqueous solution. The active pharmaceutical ingredient, a 28-amino acid acidic polypeptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, possesses a theoretical molecular weight of 3108.37 g/mol. Because clinical dosing is conventionally expressed in milligrams rather than molarity, practitioners must translate a mass-based prescription into a precise fluid volume using standard parenteral syringes [1, 2].

The U-100 designation indicates a syringe engineered to deliver 100 international units per milliliter. In the context of insulin hardware repurposed for peptide administration, 1 unit is mechanically calibrated to dispense 0.01 mL of fluid. Consequently, a full 1 mL U-100 syringe barrel corresponds to 100 units and can dispense a maximum of 0.01 mL per unit increment. Conversely, the U-40 designation refers to syringes dispensing 40 units per milliliter, where 1 unit mechanically equates to 0.025 mL. The transition between U-100 and U-40 hardware alters the volumetric delivery of a given unit count, representing a fundamental source of dosing error if the syringe scale does not match the reconstituted concentration [3, 4].

### Mathematical Modeling of Dilution Vectors

To achieve a target concentration, the administrator must calculate the total diluent volume required to suspend a known mass of peptide. The standard dilution equation dictates that C1 × V1 = C2 × V2, where C1 represents the initial stock concentration and V1 the stock volume, while C2 is the final target concentration and V2 the final total suspension volume. When reconstituting a 1 mg vial of thymosin alpha 1 peptide into a target concentration of 1000 µg/mL, the required diluent volume is 1 mL. To achieve a 500 µg/mL concentration suitable for subcutaneous injection using U-100 insulin syringes, the practitioner introduces 2 mL of bacteriostatic water, yielding 2 mL of solution containing 500 µg per mL [5].

When translating concentration into syringe units on the U-100 scale, 100 µg of thymosin alpha 1 peptide corresponds exactly to 1 unit of volumetric displacement. Therefore, a prescribed 1500 µg dose requires a withdrawal of 15 U on a U-100 instrument. On a U-40 scale, where 1 unit equals 0.025 mL, a 1000 µg/mL solution would yield 1 mg per 1 mL, meaning 0.04 mL or roughly 1.6 units would be required for a 40 µg dose. The volumetric differential between U-40 and U-100 syringes represents a 2.5-fold scale divergence for any identical mass payload [2, 5].

### Cross-Calibration Between U-40 and U-100 Systems

A frequent methodological obstacle arises when U-40 insulin hardware is erroneously employed for a solution reconstituted to a U-100 standard concentration. For example, a solution of thymosin alpha 1 peptide reconstituted at 1000 µg/mL will read exactly 100 units on a U-100 syringe when the full 1 mL is drawn. If that identical solution is instead measured using a U-40 syringe, the full 1 mL will register as only 40 units. Practitioners must therefore remain acutely aware that the numerical unit readout on the barrel is a function of both the syringe scale and the concentration of the peptide suspension, not a fixed volume [3].

To convert U-100 units to milliliters, the calculation is U/100. To convert U-40 units to milliliters, the calculation is U/40. To convert a U-100 reading to its U-40 equivalent, the mathematical operation is U_100 × 2.5. Conversely, to convert U-40 units to U-100 equivalents, U_40 / 2.5. Failure to apply this conversion when interchanging hardware will lead to a significant underdosing or overdosing of the immunomodulatory peptide, potentially compromising the pharmacological activation of toll-like receptor signaling pathways [1, 4].

### Interactive Peptide Calculator Integration

To eliminate arithmetic error and harmonize clinical workflows with biochemical precision, an interactive peptide calculator interface can be embedded directly into patient management portals. This computational tool requires four mandatory inputs: the total peptide mass in the vial in micrograms, the diluent volume added in milliliters, the prescribed subcutaneous dose in micrograms, and the selected syringe hardware format. The embedded algorithmic logic then computes the resulting concentration, the necessary unit withdrawal, and the equivalent volume in milliliters [2, 5].

For instance, entering 5000 µg of peptide mass with 2 mL of diluent yields a stock concentration of 2500 µg/mL. Selecting a prescribed dose of 1500 µg against this concentration computes a target volume of 0.6 mL. Under U-100 calibration, this volume translates to 60 U, whereas under U-40 calibration, it translates to 24 U. The calculator should dynamically update these figures to prevent manual miscalculation, ensuring that the biochemical restoration of T-cell differentiation and antiviral immunomodulation proceeds with the appropriate pharmacokinetic profile [1, 3].

### Stability, Storage, and Endotoxin Considerations in Reconstitution

The biochemical integrity of thymosin alpha 1 peptide during reconstitution is preserved through the use of sterile or bacteriostatic water for injection, avoiding saline solutions that may precipitate the acidic polypeptide. Lyophilized vials must be stored at 2 to 8 degrees Celsius and protected from light to prevent oxidative degradation of the methionine-free sequence. Once reconstituted, the peptide solution remains stable for up to 14 days when refrigerated, although single-use aliquoting is recommended to prevent repeated temperature fluctuations that could denature the secondary structure necessary for toll-like receptor interaction [2, 5].

Endotoxin contamination must be stringently excluded by utilizing depyrogenated glassware and single-use syringes, as lipopolysaccharide contamination could synergize with thymosin alpha 1 to hyperactivate innate immune cascades via TLR4, confounding the intended immunomodulatory effect. Standard aseptic technique, combined with accurate volumetric calibration and validated peptide calculator outputs, ensures that the therapeutic administration of this 28-residue polypeptide achieves consistent immunological reconstitution [1, 4].

### Summary of Dosing Logistics

The convergence of syringe calibration mathematics, volumetric dilution vectors, and digital calculator integration provides a robust framework for the parenteral delivery of thymosin alpha 1 peptide. By rigorously applying the 2.5-fold conversion factor between U-40 and U-100 platforms and by maintaining strict aseptic conditions, clinicians and researchers can confidently translate milligrams of polypeptide into precise subcutaneous units, optimizing patient outcomes in immune and defense therapeutic applications [2, 3, 5].


## Practical Applications and Research Context

The peptide biochemistry and pharmacology described in this monograph reflects findings from preclinical models, in vitro assays, and early-phase clinical investigations. Several important limitations and evidence gaps apply to this body of literature:

**Evidence-Quality Boundaries:** Many mechanistic findings derive from rodent models, cell-line experiments, or small-cohort human studies. Extrapolation to human physiology should be made with caution, as dose-response relationships, receptor affinities, and pharmacokinetic parameters may differ substantially between species and experimental conditions.

**Regulatory and Approval Status:** The research peptides discussed in this monograph are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for unsupervised human use unless specifically noted otherwise. Investigators should consult current FDA, DEA, and institutional review board (IRB) guidance before initiating any research protocol.

**Reconstitution and Dosing Uncertainty:** Concentration calculations provided via the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory models based on mass-volume-molarity relationships. Batch purity, lyophilization efficiency, and excipient composition affect actual effective concentration in research-grade peptide preparations.

**Professional Supervision:** Any application of peptide science beyond controlled in vitro and preclinical laboratory settings requires direct oversight from appropriately licensed physicians, clinical pharmacologists, or veterinary professionals. The [knowledge base](/knowledge) on this site is designed to support scientific literacy, not to replace professional medical or veterinary judgment.

**Ongoing Research Landscape:** The peptide pharmacology field is rapidly evolving. Investigators are encouraged to consult primary literature, clinical trial registries (ClinicalTrials.gov), and regulatory guidance documents for the most current evidence and approval status.


## References

[1] Giacomini E, Severa M, Cruciani M et al. "Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists.". *Expert Opin Biol Ther*, 2015. [DOI: https://doi.org/10.1517/14712598.2015.1019460](https://doi.org/10.1517/14712598.2015.1019460)

[2] Simonova MA, Ivanov I, Shoshina NS et al. "Aging and Thymosin Alpha-1.". *Int J Mol Sci*, 2025. [DOI: https://doi.org/10.3390/ijms262311470](https://doi.org/10.3390/ijms262311470)

[3] Huang L, Xu R, Fan J et al. "Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation.". *Front Cardiovasc Med*, 2026. [DOI: https://doi.org/10.3389/fcvm.2026.1827666](https://doi.org/10.3389/fcvm.2026.1827666)

[4] Solmonese L, Lofiego MF, Fazio C et al. "The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.". *Onco Targets Ther*, 2025. [DOI: https://doi.org/10.2147/ott.s527785](https://doi.org/10.2147/ott.s527785)

[5] Garaci E, Paci M, Matteucci C et al. "Phenotypic drug discovery: a case for thymosin alpha-1.". *Front Med (Lausanne)*, 2024. [DOI: https://doi.org/10.3389/fmed.2024.1388959](https://doi.org/10.3389/fmed.2024.1388959)

## Related Articles

Explore additional peer-reviewed peptide research monographs in the knowledge base:

- [LL-37: Human Cathelicidin & Host Defense](/knowledge/molecular-biology/ll-37-human-cathelicidin-antimicrobial-peptide-immunobiology)
- [KPV: Alpha-MSH Tripeptide & Immune Regulation](/knowledge/molecular-biology/kpv-alpha-msh-tripeptide-mucosal-healing-anti-inflammatory)
- [Epitalon: Pineal Peptide & Longevity](/knowledge/molecular-biology/epitalon-pineal-tetrapeptide-telomerase-activation-longevity)
- [Selank: Tuftsin Immunomodulatory Peptide](/knowledge/molecular-biology/selank-tuftsin-analog-anxiolytic-gaba-neurochemistry)
- [Peptide Reconstitution Calculator](/tools/peptide-calculator) - Calculate exact reconstitution volumes, syringe tick marks, and per-dose injection quantities